FDA approves AbbVie's Vyalev for advanced Parkinson's disease, offering personalized dosing.

The FDA has approved AbbVie's Vyalev (foscarbidopa/foslevodopa), the first 24-hour subcutaneous infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. Supported by clinical trials, Vyalev showed significant improvements in motor control compared to oral treatments. Expected Medicare coverage is anticipated by late 2025. This innovative therapy offers personalized dosing, enhancing patient symptom management.